Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 403

The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

Open access
Taïeb, David, Hicks, Rodney J., Hindié, Elif, Guillet, Benjamin A., Avram, Anca, Ghedini, Pietro, Timmers, Henri J., Scott, Aaron T., Elojeimy, Saeed, Rubello, Domenico, Virgolini, Irène J., Fanti, Stefano, Balogova, Sona, Pandit-Taskar, Neeta, Pacak, Karel·2019·European Journal of Nuclear Medicine and Molecular Imaging

Abstract

PurposeDiverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably characterise these tumours at the cellular and molecular levels and can guide therapy. Here we present updated guidelines jointly approved by the EANM and SNMMI for assisting nuclear medicine practitioners in not only the selection and performance of currently available single-photon emission computed tomography and positron emission tomography procedures, but also the interpretation and reporting of the results.MethodsGuidelines from related fields and relevant literature have been considered in consultation with leading experts involved in the management of PPGL. The provided information should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals.ConclusionSince the European Association of Nuclear Medicine 2012 guidelines, the excellent results obtained with gallium-68 (68Ga)-labelled somatostatin analogues (SSAs) in recent years have simplified the imaging approach for PPGL patients that can also be used for selecting patients for peptide receptor radionuclide therapy as a potential alternative or complement to the traditional theranostic approach with iodine-123 (123I)/iodine-131 (131I)-labelled meta-iodobenzylguanidine. Genomic characterisation of subgroups with differing risk of lesion development and subsequent metastatic spread is refining the use of molecular imaging in the personalised approach to hereditary PPGL patients for detection, staging, and follow-up surveillance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-019-04398-1

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 120 references

Cited by

See all 403

Metadata

Authors
Taïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., Virgolini, I. J., Fanti, S., Balogova, S., Pandit-Taskar, N., & Pacak, K.
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2019-06-29
Volume
46
Issue
10
Pages
2112-2137
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2954992995
Cited by
403
References
120
FWCI
35.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. https://app.cochat.ai/papers/10.1007/s00259-019-04398-1
The paper
Taïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., Virgolini, I. J., Fanti, S., Balogova, S., Pandit-Taskar, N., & Pacak, K. (2019). European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-019-04398-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.